Detailed Narrative
Q1 FY26 Performance Overview and Revenue Decline Drivers
Supriya Lifescience reported Q1 FY26 revenue of ₹145 crores, marking a 10% year-on-year decline from ₹161 crores in Q1 FY25. EBITDA also saw a 17% degrowth to ₹52 crores, though EBITDA margins remained strong at 36%. The primary reason for this decline was attributed to delays in the production facility campaign, specifically repair and maintenance work undertaken at the older Lote facility blocks (A, B, C) to support the newly operational Module E. Management expects to recover these lost sales in the second half of FY26.
Strategic Focus: Backward Integration and Market Expansion
The company's backward integration efforts continued to yield results, with the percentage rising to 81% in Q1 FY26 from 69% in Q1 FY25, strengthening control over key inputs and reducing external dependence. Exports contributed 85% of Q1 FY26 revenue, with the European market share increasing to 41% from 36% in Q1 FY25. This strategic focus on regulated markets and backward integration is expected to sustain EBITDA margins in the 33-35% range.
CDMO and New Product Pipeline Update
Supriya Lifescience is actively pursuing its CDMO strategy, with the Ambernath site commencing validation campaigns for liquid anesthetics and oral solids, expecting commercial contributions from Q4 FY26. The company plans 3-4 new product launches in FY26 across therapeutic areas like anesthetics, antidiabetics, and ADHD. The anesthetic molecule has a market size of $300 million, ADHD $90 million, and cardiovascular intermediate $100 million, indicating a focus on larger global opportunities.
Whey Protein and DSM Contract Progress
The Whey Protein contract is in its final stage, expected to be signed by the end of Q2 FY26, with small revenue generation anticipated from Q4 FY26. The long-term potential for this product is significant, aiming for ₹40-50 crores in 3-4 years and scaling up to ₹100 crores in 4-5 years. However, the FY26 volume guidance for Whey Protein was revised downwards to about 50 tonnes from the earlier 100 metric tons. The DSM contract is on track to contribute ₹30-35 crores in revenue for the full FY26, with CEP approval already received for Europe.
Contrast Media and Regulatory Filings
The contrast media product is scheduled for launch in Q2 FY26. Management is confident in gaining a 20-25% market share for this product within 3-4 years, leveraging cost and technology advantages, along with full backward integration. The company also plans to significantly increase its US DMF filings in the next 3-4 years for new products, indicating a stronger focus on the US regulated market going forward⏳.
Patalganga Expansion and Future Capacity
The environmental clearance for the Patalganga site has been received, and the company expects to take possession within 15-20 days, with construction activity to commence thereafter. This new site, planned for API and finished formulation, will support the next leg of expansion and ensure sufficient manufacturing capacity to handle growth beyond the guided 20% annual rate, especially for larger molecules being targeted.